OMER

Omeros Corporation

Jul 16 • 04:00PM ET

3.51

Dollar change -0.10
Percentage change -2.77	%

Healthcare • Biotechnology • USA • NASD

Peers: IONS BMRN NBIX INCY SRPT EXEL GILD VRTX REGN AMGN

| Held by: IWM VTI VXF IWO SCHA VTWO IWC ITOT IWN PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.64	Insider Own	4.46%	Shs Outstand	58.06M	Perf Week	3.85%
Market Cap	205.66M	Forward P/E	-	EPS next Y	-0.06	Insider Trans	0.00%	Shs Float	55.98M	Perf Month	3.24%
Enterprise Value	568.30M	PEG	-	EPS next Q	-0.44	Inst Own	47.15%	Short Float	24.15%	Perf Quarter	-49.79%
Income	-153.09M	P/S	-	EPS this Y	31.51%	Inst Trans	3.38%	Short Ratio	13.40	Perf Half Y	-60.07%
Sales	0.00M	P/B	-	EPS next Y	96.55%	ROA	-52.43%	Short Interest	13.52M	Perf YTD	-64.47%
Book/sh	-3.68	P/C	3.92	EPS next 5Y	-	ROE	-	52W High	13.60 -74.19%	Perf Year	-17.80%
Cash/sh	0.89	P/FCF	-	EPS past 3/5Y	-14.69% -9.58%	ROIC	-103.83%	52W Low	2.95 18.98%	Perf 3Y	-11.59%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.55% 7.70%	Perf 5Y	-73.83%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-33.92%	Oper. Margin	-	ATR (14)	0.28	Perf 10Y	-78.09%
Dividend Ex-Date	-	Quick Ratio	1.16	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.86	Recom	1.80
Dividend Gr. 3/5Y	- -	Current Ratio	1.16	EPS Q/Q	8.87%	SMA20	5.98%	Beta	2.24	Target Price	30.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-4.92%	Rel Volume	0.79	Prev Close	3.61
Employees	202	LT Debt/Eq	-	Earnings	May 15 AMC	SMA200	-47.08%	Avg Volume	1.01M	Price	3.51
IPO	Oct 08, 2009	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.51% -25.00%	Trades		Volume	802,057	Change	-2.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-10-25	Initiated	H.C. Wainwright	Buy	$9
Dec-23-24	Initiated	D. Boral Capital	Buy	$36
Nov-14-24	Initiated	Rodman & Renshaw	Buy	$9
Dec-08-22	Downgrade	UBS	Buy → Neutral	$12 → $2
Nov-08-22	Downgrade	BofA Securities	Neutral → Underperform	$8 → $3
Jun-08-22	Downgrade	BofA Securities	Buy → Neutral	$12 → $4
Oct-08-21	Downgrade	JP Morgan	Neutral → Underweight
Oct-01-21	Downgrade	Wedbush	Neutral → Underperform
Oct-01-21	Downgrade	Maxim Group	Buy → Hold
Sep-27-21	Initiated	JP Morgan	Neutral	$15
Feb-01-21	Initiated	UBS	Buy	$25
Oct-20-20	Initiated	BofA Securities	Buy	$21
Aug-21-20	Reiterated	H.C. Wainwright	Buy	$34 → $32
Aug-14-20	Reiterated	Maxim Group	Buy	$25 → $20
May-06-19	Initiated	Cantor Fitzgerald	Overweight	$26
Jul-12-18	Initiated	Seaport Global Securities	Buy	$30
Mar-23-18	Downgrade	Wedbush	Outperform → Neutral	$47 → $19
Mar-05-18	Downgrade	Needham	Buy → Hold
Nov-08-17	Initiated	H.C. Wainwright	Buy	$30
May-11-17	Downgrade	Cantor Fitzgerald	Buy → Neutral	$21 → $15

Show Previous Ratings

Jun-27-25 08:30AM	Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA (Business Wire)
Jun-24-25 08:30AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) +5.96%
Jun-03-25 09:35AM	Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER) (Zacks)
May-16-25 08:13AM	Q1 2025 Omeros Corp Earnings Call (Thomson Reuters StreetEvents) -18.61%
03:13AM	Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ... (GuruFocus.com)
04:34PM	Loading…
May-15-25 04:34PM	Omeros: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Omeros Corporation Reports First Quarter 2025 Financial Results (Business Wire)
May-12-25 05:05PM	Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025 (Business Wire) -38.59% +16.73%
08:41AM	Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026 (Business Wire)
May-06-25 09:16AM	FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date (Business Wire) -6.90%
Apr-10-25 09:10AM	Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros Proprietary OncotoX-AML Clinical Program (Business Wire) -9.85%
Apr-08-25 09:00AM	Omeros Corporation To Introduce Its Proprietary T-CAT Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases (Business Wire) -12.55%
Apr-01-25 09:27AM	Q4 2024 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
03:03AM	Omeros Corp (OMER) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... (GuruFocus.com)
Mar-31-25 08:57PM	Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:17PM	Loading…
04:17PM	Omeros: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results (Business Wire)
Mar-26-25 09:15AM	Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025 (Business Wire) -6.99%
Mar-24-25 07:58AM	Omeros to activate site for Phase III programme of zaltenibart for PNH (Clinical Trials Arena)
Mar-21-25 09:15AM	Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program (Business Wire)
Mar-13-25 09:00AM	Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Companys OMS527 Program to Treat Cocaine Use Disorder (Business Wire)
Feb-21-25 09:21AM	Omeros announces results for narsoplimab expanded access program (TipRanks)
Feb-20-25 09:10AM	Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA (Business Wire)
Feb-14-25 09:00AM	Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings (Business Wire)
Feb-10-25 09:00AM	Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program (Business Wire)
Jan-16-25 09:15AM	Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint (Business Wire)
Dec-19-24 10:46AM	Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges (GuruFocus.com) +37.27%
09:15AM	Omeros' Narsoplimab Meets its Pivotal Trial Primary Endpoint - Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA (Business Wire)
Dec-10-24 12:22PM	Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges (Insider Monkey) -7.38%
08:45AM	Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting (Business Wire)
08:45AM	Loading…
Dec-02-24 08:45AM	Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting (Business Wire) +5.29%
Nov-22-24 02:31PM	Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News (GuruFocus.com) +41.14%
Nov-21-24 09:15AM	Omeros Corporation Provides Update on Progress Toward BLA Resubmission (Business Wire) +28.19%
Nov-14-24 02:01PM	Q3 2024 Omeros Corp Earnings Call (Thomson Reuters StreetEvents) +65.87%
02:15AM	Omeros Corp (OMER) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Adjustments (GuruFocus.com)
Nov-13-24 04:17PM	Omeros: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-11-24 04:11PM	Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024 (Business Wire)
Oct-24-24 08:45AM	FDA Grants Rare Pediatric Disease Designation to Omeros MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy (Business Wire)
Aug-07-24 05:16PM	Omeros: Q2 Earnings Snapshot (Associated Press Finance) -5.03% -5.78%
04:02PM	Omeros Corporation Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-05-24 04:02PM	Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024 (Business Wire) -10.68%
Jun-04-24 09:00AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) -6.16%
Jun-03-24 09:00AM	Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028 (Business Wire) +20.83%
May-16-24 01:10PM	Q1 2024 Omeros Corp Earnings Call (Thomson Reuters StreetEvents) -20.62%
03:10AM	Omeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ... (GuruFocus.com)
May-15-24 08:55PM	OMER Stock Earnings: Omeros Misses EPS for Q1 2024 (InvestorPlace)
04:11PM	Omeros: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports First Quarter 2024 Financial Results (Business Wire)
May-10-24 08:50AM	Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024 (Business Wire)
May-09-24 08:50AM	Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress (Business Wire)
Apr-02-24 12:41PM	Q4 2023 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
11:22AM	Omeros Corporation (NASDAQ:OMER) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-01-24 09:53PM	OMER Stock Earnings: Omeros Misses EPS for Q4 2023 (InvestorPlace) -7.54%
05:32PM	Omeros Corp (OMER) Reports Fourth Quarter and Year-End 2023 Financial Results (GuruFocus.com)
04:17PM	Omeros: Q4 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results (Business Wire)
Mar-27-24 08:30AM	Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 (Business Wire)
Mar-17-24 10:02AM	Sleeping Giants: 3 Picks With Massive Upside by Mid-Decade (InvestorPlace)
Feb-20-24 09:00AM	Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy (Business Wire)
Feb-07-24 09:34AM	3 Sleeper Stocks Under $15 Ready to Explode by 2029 (InvestorPlace)
Feb-01-24 09:11AM	Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust (Business Wire)
Dec-24-23 01:08PM	7 Short-Squeeze Stocks That Are Screaming for Speculation (InvestorPlace)
Nov-11-23 03:01PM	Omeros Corporation (NASDAQ:OMER) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 09:43AM	Q3 2023 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
Nov-09-23 04:33PM	Omeros: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	Omeros Corporation Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-06-23 08:00AM	Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023 (Business Wire) +6.25%
Nov-03-23 09:05AM	Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy (Business Wire)
Nov-02-23 09:05AM	Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting (Business Wire) +7.96%
Oct-19-23 08:30AM	Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer (Business Wire) -10.32%
Oct-16-23 08:36AM	Omeros stops kidney disease phase 3 after interim review fail, cutting thread holding up stock price (FierceBiotech.com) -32.16%
07:59AM	UPDATE 1-Omeros to terminate kidney disease trial as therapy fails late-stage study (Reuters)
07:44AM	Omeros to shut kidney disease trial as therapy fails in late-stage study (Reuters)
07:30AM	Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy (Business Wire)
Aug-09-23 08:08AM	Omeros: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Omeros Corporation Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-04-23 08:00AM	Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023 (Business Wire)
Jun-21-23 08:30AM	Omeros Announces Webcast Details for Annual Meeting of Shareholders (Business Wire) -7.31%
Jun-12-23 02:47PM	Why Shares of Omeros Dropped on Monday (Motley Fool) -14.53%
08:45AM	Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress (Business Wire)
Jun-01-23 11:00AM	Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress (Business Wire) +17.42%
May-09-23 04:41PM	Omeros: Q1 Earnings Snapshot (AP Finance) +21.20%
04:02PM	Omeros Corporation Reports First Quarter 2023 Financial Results (Business Wire)
May-04-23 04:06PM	Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023 (Business Wire)
Apr-25-23 09:25AM	Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (Business Wire) -5.32%
Apr-10-23 08:45AM	Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program (Business Wire) +7.31%
Mar-29-23 09:07AM	Avis Budget Group and Vulcan Materials have been highlighted as Zacks Bull and Bear of the Day (Zacks) +9.42%
Mar-28-23 09:34AM	3 Medical Stocks Creating Wealth Despite Macro Challenges (Zacks)
Mar-14-23 11:11AM	Omeros Corporation (NASDAQ:OMER) Q4 2022 Earnings Call Transcript (Insider Monkey) +9.28%
10:06AM	Q4 2022 Omeros Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-13-23 04:02PM	Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results (Business Wire) +5.83%
Mar-10-23 03:37PM	Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank (Business Wire) -10.93%
Mar-07-23 09:00AM	Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023 (Business Wire)
Feb-09-23 02:43PM	Why Omeros Stock Bolted Higher This Week (Motley Fool)
Feb-06-23 11:30AM	Why Omeros Corporation Stock Is Skyrocketing Today (Motley Fool) +61.17%
08:50AM	Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical (Business Wire)
Nov-09-22 04:02PM	Omeros Corporation Reports Third Quarter 2022 Financial Results (Business Wire) -11.88% -5.85%
Nov-08-22 08:30AM	Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab (Business Wire)
Nov-04-22 09:00AM	Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022 (Business Wire) -5.03%

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OMER

Omeros Corporation

Upgrade your FINVIZ experience